{
    "nct_id": "NCT03761056",
    "official_title": "A Phase 2 Multicenter Study Evaluating the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Subjects With High-Risk Large B-Cell Lymphoma (ZUMA-12)",
    "inclusion_criteria": "* Histologically confirmed large B-cell lymphoma\n* High-grade large B-cell lymphoma\n* Individuals must have a positive interim positron emission tomography (PET) (Deauville PET score of 4 or 5) after 2 cycles (PET2+) of chemoimmunotherapy\n* No evidence, suspicion and/or history of central nervous system (CNS) involvement of lymphoma\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Absolute neutrophil count ≥ 1000/μL\n* Platelet count ≥ 75,000/μL\n* Absolute lymphocyte count ≥ 100/μL\n* Adequate renal, hepatic, pulmonary, and cardiac function defined as:\n\n  * Creatinine clearance (as estimated by Cockcroft Gault) ≥ 60 mL/min\n  * Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 upper limit of normal (ULN)\n  * Total bilirubin ≤1.5 mg/dL, except in individuals with Gilbert's syndrome\n* Cardiac ejection fraction ≥ 50%, no evidence of pericardial effusion as determined by an echocardiogram (ECHO), and no clinically significant electrocardiogram (ECG) findings\n* No clinically significant pleural effusion\n* Baseline oxygen saturation > 92% on room air\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of malignancy other than nonmelanoma skin cancer or carcinoma in situ (eg cervix, bladder, breast) unless disease free for at least 3 years\n* History of Richter's transformation of chronic lymphocytic leukemia or primary mediastinal B-cell lymphoma\n* History of autologous or allogeneic stem cell transplant\n* Prior CD19-targeted therapy\n* Prior chimeric antigen receptor therapy or other genetically modified T-cell therapy\n* Presence or suspicion of fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management\n* History of human immunodeficiency virus (HIV) infection or acute or chronic active hepatitis B or C infection\n* Presence of any indwelling line or drain dedicated central venous access catheters, such as a Port-a-Cath or Hickman catheter, are permitted\n* Individuals with detectable cerebrospinal fluid malignant cells, brain metastases, or active CNS lymphoma\n* History or presence of CNS disorder, such as seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement\n* History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months of enrollment\n* History of autoimmune disease resulting in end organ injury or requiring systemic immunosuppression/systemic disease modifying agents within the last 2 years\n* History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months of enrollment\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
    "miscellaneous_criteria": "Key"
}